分别是Chiesi的CHF6001和Verona的ensifentrine。CHF6001是一种新型的吸入式PDE4抑制剂,对慢阻肺具有非常高的效力,研究表明,CHF6001显著降低痰中各种炎症生物标志物,还显著降低了血液中的SP-D水平。而Ensifentrine(RPL554)是一种设计为雾化吸入的磷酸二酯酶3/4(PDE3/4)抑制剂,双重抑制PDE3和PDE4对气道平滑肌...
Chiesi Farmaceut SpA Largo Belloli 11-A I-43122 Parma ItalyEuropean journal of pharmaceutical sciencesCenacchi, V., Salvadori, M., Riccardi, B., Brogin, G., Ghiglieri, A., Messina, M., et al. (2018). Role of efflux transporters in the absorption, distribution and elimination in ...
The new methodology was used to investigate the inhalation PK and lung retention in the rat of the novel Chiesi PDE4 inhibitor CHF6001 in three exposure models of the PreciseInhale platform: nose-only, intratracheally intubated rat, and the isolated, ventilated, and perfused rat lung. Results ...
ChiesiJournal of aerosol medicine and pulmonary drug deliveryFioni A, Selg E, Cenacchi V, Acevedo F, Brogin G, Gerde P, et al. Investigation of lung pharmacokinetics of the novel PDE4 inhibitor CHF6001 in preclinical models: evaluation of the PreciseInhale technology. J Aerosol Med Pulm ...
Daniele SpinabelliDepartment of DMPK, Chiesi Farmaceutici Spa, Parma, Italy andGiandomenico BroginDepartment of DMPK, Chiesi Farmaceutici Spa, Parma, Italy andPaola PucciniDepartment of DMPK, Chiesi Farmaceutici Spa, Parma, Italy andDaniele PezzettaDepartment of DMPK, Accelera, Nerviano (MI), Italy...